Collecting real-world data on the management of metastatic colorectal cancer (mCRC)

The purpose of PROMETCO is to provide real-world data on overall survival, treatment patterns, associated effectiveness and safety, and impact on patients with mCRC throughout the continuum of care1

ABOUT PROMETCO

CRC is a major public health burden2,3

  • 1.85 million new cases in 2018
  • 881,000 deaths in 2018
  • <10% survival rate in patients with stage IV CRC

Latest news

Study status

18

Participating
countries

92

Investigational sites

88 recruiting

4 non-recruiting

690

/1000

Patients enrolled

READ MORE

Why PROMETCO

PROMETCO rationale

Advances in treatment of mCRC in the past 15 years have improved patient survival to ~30 months based on data from RCTs4

Data from prospective real-world studies are lacking

PROMETCO aims to address this gap

PROMETCO study objectives

Study objectives are to describe the following for mCRC patients in a real-world setting:

Overall survival

Treatment patterns for mCRC throughout the continuum of care

Effectiveness/safety of treatments in a real-world setting

Reasons for therapy discontinuations and choice of subsequent treatment

Adherence to national and ESMO guidelines

Healthcare resource utilization

Patient-reported outcomes

PROMETCO

Rapid Reference Leaflet